Proteonomix Inc., (OTCBB:PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease. StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary.

The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

PROT is planning to lead the research community into the future by introducing a new platform for growing contaminant-fee human stem cells that will serve as a catalyst for bringing feasible therapies to market.

With umbilical cord blood stem cells already being recognized as a viable treatment for more than 80 diseases and that number continuing to grow in the future, PROT is also preparing to establish a cord blood bank that employs proprietary technology that will lead to a significant increase in the donor-recipient match rate. PROT will also be launching a genetic diversity program to increase the currently under-represented minority groups in the pool of available cord blood stem cell units.

PROT is working with top scientists and institutions around the world.

To learn more about visit their informative website: www.proteonomix.com

********************

Prana Biotechnology Ltd, PRAN

Prana Biotechnology Ltd, (NasdaqCM: PRAN) recently announced that Professor Ashley Bush, a co-founding scientist of Prana and a member of the Company's R&D Advisory Board, has in conjunction with the University of Melbourne, Australia, and Harvard Medical School, Boston, published an article that appears online entitled: "Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's Disease" scheduled for the September 17 edition of Cell, the prestigious peer-reviewed, international biological research journal.

Prana's therapeutic strategy is to restore normal metal levels and distribution in the brain, such as zinc, which typically changes with aging and is exacerbated in Alzheimer's Disease, resulting in (i) reduced synaptic function and (ii) beta-amyloid reacting with the metals to form toxic oligomers that impair cognition.

The Cell publication now adds a third metal-dependent event, iron accumulation, which if left untreated, contributes to neuronal death in the Alzheimer's brain

PBT2 is Prans'a lead Alzheimer's drug which helps the zinc chaperone transport from the brain beta-amyloid deposits and returns it to neurons to facilitate normal neurotransmission. This drug can be a new and exciting strategy for treating or preventing Alzheimer's Disease.

The published report is the most comprehensive validation to date of the importance of brain metals, which are the key therapeutic target of PBT2, in treating Alzheimer's Disease.

Prana Biotechnology was established to commercialize research into Alzheimer's Disease, Huntington's Disease and other major age-related neurodegenerative disorders.

For further information please visit the Company's web site at www.pranabio.com

********************

Hansen Medical Inc. (NASDAQ:HNSN)

Controlled Commercial Launch of Flexible, Irrigated Catheter Commences in Europe

HNSN, a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, recently announced the first sale of its Lynx Irrigated Ablation Catheter and the successful treatment of the first patients using the device. Physicians at John Radcliffe Hospital in Oxford, England performed the first clinical cases using the Lynx catheter to treat atrial fibrillation (AF), the world's most common cardiac arrhythmia that affects millions of people worldwide and is associated with increased long-term risk for severe conditions including stroke.

"The success of Lynx in Europe and, ultimately, in other markets are central to our move into the higher revenue, higher margin opportunities provided by the sale of proprietary therapy systems," said Bruce J Barclay, president and CEO of Hansen Medical. "We are committed to providing technology that enables clinicians to offer better treatment options to their patients, while driving better economics for the healthcare system."

HNSN, based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies.

To learn more about HNSN visit: http://www.hansenmedical.com

___

******************************************************************

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

******************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period